ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest eating disorders news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks eating disorders across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Novo Nordisk and Eli Lilly spent $700 million marketing GLP-1 drugs Wegovy, Ozempic, Zepbound, and Mounjaro in the first nine months of 2025. The advertising surge makes weight-loss content inescapable online, triggering disordered eating behaviors in people in recovery. A TikTok algorithm study found users with a history of disordered eating receive more toxic content.
Summaries by ByteBrief